Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Acknowledgements This work was partly supported by Allergan Inc., Irvine, CA, USA
7 , Cd006521 (2017)
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
Maxiliv Injection
US$ 25.69
US$ 24.20
US$ 21.50
US$ 26.13
US$ 28.72
US$ 22.29
US$ 20.00
US$ 25.45
US$ 20.77
